PreeclampsiaScreen T1 by PerkinElmer, Inc.

Manufacturer PerkinElmer, Inc.
PreeclampsiaScreen™ T1 enables accurate detection of early onset preeclampsia risk, allowing for earlier intervention and management of the pregnancy.PreeclampsiaScreen™ T1 is the first screening test in the U.S. to measure three biochemical markers in the mother's serum associated with preeclampsia: PAPP-A (pregnancy-associated plasma protein-A); PlGF (placental growth factor) and AFP (alpha fetoprotein). Together, these three biochemical markers can contribute to accurate prediction of risk fo... Read more


PreeclampsiaScreen T1 by PerkinElmer, Inc.  product image
PreeclampsiaScreen T1

PerkinElmer, Inc.

The supplier does not provide quotations for this particular product through SelectScience. You can search for similar products in our product directory.



0 Scientists have reviewed this product


Write the First Review

No Reviews

PreeclampsiaScreen™ T1 enables accurate detection of early onset preeclampsia risk, allowing for earlier intervention and management of the pregnancy.

PreeclampsiaScreen™ T1 is the first screening test in the U.S. to measure three biochemical markers in the mother's serum associated with preeclampsia: PAPP-A (pregnancy-associated plasma protein-A); PlGF (placental growth factor) and AFP (alpha fetoprotein). Together, these three biochemical markers can contribute to accurate prediction of risk for early onset preeclampsia.

PreeclampsiaScreen T1 Benefits:

  • Highest sensitivity in a biochemical screen. Provides a detection rate of 60% at a 5% false positive rate for early onset preeclampsia when combined with patient history and demographics.
  • 91% sensitivity when combined with 2 additional biophysical markers. Detection rate as high as 91% at a 5% false positive rate for early onset preeclampsia when combined with two additional biophysical markers: uterine artery Doppler pulsatility index (UtAD-PI) and mean arterial blood pressure (MAP).
  • Practical. Helps you identify those patients who may require increased vigilance.
  • Convenient. Can be ordered at the same gestational age/patient visit as first trimester aneuploidy screening.
  • Timely. Results can be obtained as early as 10 weeks 2 days' gestation.